|
1
|
Kakehi Y: Watchful waiting as a treatment
option for localized prostate cancer in the PSA era. Jpn J Clin
Oncol. 33:1–5. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Santanam U, Banach-Petrosky W, Abate-Shen
C, Shen MM, White E and DiPaola RS: Atg7 cooperates with Pten loss
to drive prostate cancer tumor growth. Genes Dev. 30:399–407. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miftakhova R, Hedblom A, Semenas J,
Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP,
Maitland NJ, et al: Cyclin A1 and P450 aromatase promote metastatic
homing and growth of stem-like prostate cancer cells in the bone
marrow. Cancer Res. 76:2453–2464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu
G and Ye CJ: Genetic and epigenetic heterogeneity in cancer: A
genome-centric perspective. J Cell Physiol. 220:538–547. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ulaganathan VK, Sperl B, Rapp UR and
Ullrich A: Germline variant FGFR4 p.G388R exposes a
membrane-proximal STAT3 binding site. Nature. 528:570–574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Blattner M, Liu D, Robinson BD, Huang D,
Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V,
et al: SPOP mutation drives prostate tumorigenesis in vivo through
coordinate regulation of PI3K/mTOR and AR signaling. Cancer Cell.
31:436–451. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Q, Song R, Ortogero N, Zheng H, Evanoff
R, Small CL, Griswold MD, Namekawa SH, Royo H, Turner JM and Yan W:
The RNase III enzyme DROSHA is essential for microRNA production
and spermatogenesis. J Biol Chem. 287:25173–25190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kent OA and Mendell JT: A small piece in
the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 25:6188–6196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hudson RS, Yi M, Esposito D, Watkins SK,
Hurwitz AA, Yfantis HG, Lee DH, Borin JF, Naslund MJ, Alexander RB,
et al: MicroRNA-1 is a candidate tumor suppressor and prognostic
marker in human prostate cancer. Nucleic Acids Res. 40:3689–3703.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rane JK, Scaravilli M, Ylipää A, Pellacani
D, Mann VM, Simms MS, Nykter M, Collins AT, Visakorpi T and
Maitland NJ: MicroRNA expression profile of primary prostate cancer
stem cells as a source of biomarkers and therapeutic targets. Eur
Urol. 67:7–10. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks
JJ, Thaxton CS and Mirkin CA: Circulating microRNA signature for
the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci
USA. 113:10655–10660. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li X, Wan X, Chen H, Yang S, Liu Y, Mo W,
Meng D, Du W, Huang Y, Wu H, et al: Identification of miR-133b and
RB1CC1 as independent predictors for biochemical recurrence and
potential therapeutic targets for prostate cancer. Clin Cancer Res.
20:2312–2325. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ling XH, Han ZD, Xia D, He HC, Jiang FN,
Lin ZY, Fu X, Deng YH, Dai QS, Cai C, et al: MicroRNA-30c serves as
an independent biochemical recurrence predictor and potential tumor
suppressor for prostate cancer. Mol Biol Rep. 41:2779–2788. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ling XH, Chen ZY, Luo HW, Liu ZZ, Liang
YK, Chen GX, Jiang FN and Zhong WD: BCL9, a coactivator for
Wnt/β-catenin transcription, is targeted by miR-30c and is
associated with prostate cancer progression. Oncol Lett.
11:2001–2008. 2016.PubMed/NCBI
|
|
15
|
Yu F, Deng H, Yao H, Liu Q, Su F and Song
E: Mir-30 reduction maintains self-renewal and inhibits apoptosis
in breast tumor-initiating cells. Oncogene. 29:4194–4204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Martinez I, Cazalla D, Almstead LL, Steitz
JA and DiMaio D: miR-29 and miR-30 regulate B-Myb expression during
cellular senescence. Proc Natl Acad Sci USA. 108:522–527. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D,
Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, et al: miR-30-5p
functions as a tumor suppressor and novel therapeutic tool by
targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res.
74:1801–1813. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pino I, Pío R, Toledo G, Zabalegui N,
Vicent S, Rey N, Lozano MD, Torre W, García-Foncillas J and
Montuenga LM: Altered patterns of expression of members of the
heterogeneous nuclear ribonucleoprotein (hnRNP) family in lung
cancer. Lung Cancer. 41:131–143. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zerbe LK, Pino I, Pio R, Cosper PF,
Dwyer-Nield LD, Meyer AM, Port JD, Montuenga LM and Malkinson AM:
Relative amounts of antagonistic splicing factors, hnRNP A1 and
ASF/SF2, change during neoplastic lung growth: Implications for
pre-mRNA processing. Mol Carcinog. 41:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Miguel FJ, Sharma RD, Pajares MJ,
Montuenga LM, Rubio A and Pio R: Identification of alternative
splicing events regulated by the oncogenic factor SRSF1 in lung
cancer. Cancer Res. 74:1105–1115. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Anczuków O, Akerman M, Cléry A, Wu J, Shen
C, Shirole NH, Raimer A, Sun S, Jensen MA, Hua Y, et al:
SRSF1-regulated alternative splicing in breast cancer. Mol Cell.
60:105–117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moore MJ, Wang Q, Kennedy CJ and Silver
PA: An alternative splicing network links cell-cycle control to
apoptosis. Cell. 142:625–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olshavsky NA, Comstock CE, Schiewer MJ,
Augello MA, Hyslop T, Sette C, Zhang J, Parysek LM and Knudsen KE:
Identification of ASF/SF2 as a critical, allele-specific effector
of the cyclin D1b oncogene. Cancer Res. 70:3975–3984. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ezponda T, Pajares MJ, Agorreta J,
Echeveste JI, López-Picazo JM, Torre W, Pio R and Montuenga LM: The
oncoprotein SF2/ASF promotes non-small cell lung cancer survival by
enhancing survivin expression. Clin Cancer Res. 16:4113–4125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Anczuków O, Rosenberg AZ, Akerman M, Das
S, Zhan L, Karni R, Muthuswamy SK and Krainer AR: The splicing
factor SRSF1 regulates apoptosis and proliferation to promote
mammary epithelial cell transformation. Nat Struct Mol Biol.
19:220–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang Z, Zhang L, Yi X and Yu X:
Diagnostic and prognostic values of tissue hsa-miR-30c and
hsa-miR-203 in prostate carcinoma. Tumour Biol. 37:4359–4365. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kachakova D, Mitkova A, Popov E, Popov I,
Vlahova A, Dikov T, Christova S, Mitev V, Slavov C and Kaneva R:
Combinations of serum prostate-specific antigen and plasma
expression levels of let-7c, miR-30c, miR-141, and miR-375 as
potential better diagnostic biomarkers for prostate cancer. DNA
Cell Biol. 34:189–200. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ren Q, Liang J, Wei J, Basturk O, Wang J,
Daniels G, Gellert LL, Li Y, Shen Y, Osman I, et al: Epithelial and
stromal expression of miRNAs during prostate cancer progression. Am
J Transl Res. 6:329–339. 2014.PubMed/NCBI
|
|
30
|
Verduci L, Simili M, Rizzo M, Mercatanti
A, Evangelista M, Mariani L, Rainaldi G and Pitto L: microRNA
(miRNA)-mediated interaction between leukemia/lymphoma-related
factor (LRF) and alternative splicing factor/splicing factor 2
(ASF/SF2) affects mouse embryonic fibroblast senescence and
apoptosis. J Biol Chem. 285:39551–39563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu LL, Xie N, Sun S, Plymate S, Mostaghel
E and Dong X: Mechanisms of the androgen receptor splicing in
prostate cancer cells. Oncogene. 33:3140–3150. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Busà R, Geremia R and Sette C: Genotoxic
stress causes the accumulation of the splicing regulator Sam68 in
nuclear foci of transcriptionally active chromatin. Nucleic Acids
Res. 38:3005–3018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karni R, Hippo Y, Lowe SW and Krainer AR:
The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl
Acad Sci USA. 105:15323–15327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hsieh AC, Liu Y, Edlind MP, Ingolia NT,
Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ, et
al: The translational landscape of mTOR signalling steers cancer
initiation and metastasis. Nature. 485:55–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sinclair CS, Rowley M, Naderi A and Couch
FJ: The 17q23 amplicon and breast cancer. Breast Cancer Res Treat.
78:313–322. 2003. View Article : Google Scholar : PubMed/NCBI
|
